Associations of combined lifestyle and genetic risks with incident psoriasis: A prospective cohort study among UK Biobank participants of European ancestry - 16/07/22
, Yi Xiao, PhD a, c, d, Danrong Jing, MD a, Guanxiong Zhang, PhD a, Juan Su, PhD a, c, d, Shuhong Lin, PhD e, ⁎ , Xiang Chen, PhD a, c, d, f, ⁎ , Hong Liu, PhD a, c, d, ⁎ Abstract |
Background |
Whether the lifestyle is associated with the risk of psoriasis in the presence of different genetic risk levels remains unknown.
Objective |
To examine the gene-behavior interaction in association with incident psoriasis.
Methods |
This study is based on the data from the UK Biobank, which recruited 500,000 participants. Genetic risk was categorized into low, intermediate, and high groups. The lifestyle score comprised the body mass index, smoking, physical activity, and diet and was also categorized into the ideal, intermediate, and poor groups. Within each genetic risk group, the risks of incident psoriasis associated with each lifestyle level were investigated and compared with the low genetic risk and ideal lifestyle group.
Results |
Compared with the low genetic risk and ideal lifestyle group, the poor lifestyle and high genetic risk group was associated with a hazard ratio of up to 4.625 (95% confidence interval [CI], 2.920-7.348) for psoriasis. There was no interaction between genetic risk and lifestyle. The population attributable fractions of lifestyle and genetic risk were 32.2% (95% CI, 25.1%-38.6%) and 13.0% (95% CI, 3.2%-21.8%), respectively.
Limitations |
No verification in other independently ascertained populations.
Conclusion |
Lifestyle factors are predictive of the risk of incident psoriasis independent of genetic risk, and the relative impact of lifestyle factors was greater than that of genetic risk.
Le texte complet de cet article est disponible en PDF.Key words : genetic risk, interactions, lifestyle, psoriasis
Abbreviations used : BMI, CI, GWAS, HR, PAF, PRS, SNP
Plan
| Drs Shen, Xiao, and Jing contributed equally to this article. |
|
| Funding sources: Supported by the National Key Research and Development Program of China (2019YFE0120800, 2019YFA0111600), the Natural Science Foundation of China for Outstanding Young Scholars (82022060), the National Natural Science Foundation of China (81874242, 31800979), and the Natural Science Foundation of Hunan Province for Outstanding Young Scholars (2019JJ30040). |
|
| IRB approval status: This study was based on UK Biobank (Application Number: 55242, 55257). The UK Biobank received ethical approval from the North West Multi-Center Research Ethics Committee (11/NW/0382), and all participants provided informed consent. No ethics approval was acquired for the analyses using summary statistics. The contributing studies to the consortium received ethical approval from their specific institutional review boards, and consent was obtained from all participants. |
|
| Reprints not available from the authors. |
Vol 87 - N° 2
P. 343-350 - août 2022 Retour au numéro
Article précédent
- Oral tyrosine kinase 2 inhibitor PF-06826647 demonstrates efficacy and an acceptable safety profile in participants with moderate-to-severe plaque psoriasis in a phase 2b, randomized, double-blind, placebo-controlled study
- Christopher Tehlirian, Ravi Shankar P. Singh, Vivek Pradhan, Erika S. Roberts, Sanela Tarabar, Elena Peeva, Michael S. Vincent, Jeremy D. Gale
- Phase 3 efficacy and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis after switching from dupilumab (JADE EXTEND)
- Vivian Y. Shi, Tina Bhutani, Luz Fonacier, Mette Deleuran, Stephen Shumack, Hernan Valdez, Fan Zhang, Gary L. Chan, Michael C. Cameron, Natalie C. Yin
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?